Pluristem Therapeutics Inc. Forecast, price target & analysts
Pluristem Therapeutics Inc. Target price 2026 - Analyst rating & recommendation
Pluristem Therapeutics Inc. Classifications & Recommendation
Pluristem Therapeutics Inc. Price Target
| Target Price | $12.24 |
| Price | $1.05 |
| Potential |
1,065.71%
register free of charge
|
| Number of Estimates | 3 |
|
3 Analysts have issued a price target Pluristem Therapeutics Inc. 2027 .
The average Pluristem Therapeutics Inc. target price is $12.24.
This is
1,065.71%
register free of charge
$12.60
1,100.00%
register free of charge
$12.12
1,054.29%
register free of charge
|
|
| A rating was issued by 7 analysts: 6 Analysts recommend Pluristem Therapeutics Inc. to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Pluristem Therapeutics Inc. stock has an average upside potential 2027 of
1,065.71%
register free of charge
|
Sales and Margin forecast 2027, 2028 & 2029
| Jun '26 |
2027 Estimates |
|
|---|---|---|
| Revenue Million $ | 1.02 | 10.39 |
| 23.88% | 918.53% | |
| Net Margin | -2,335.29% | -201.84% |
| 38.59% | 91.36% |
3 Analysts have issued a sales forecast Pluristem Therapeutics Inc. 2027 . The average Pluristem Therapeutics Inc. sales estimate is
This results in the following potential growth metrics:
Revenue Estimates
| 2026 | $1.0m | 23.88% |
|---|---|---|
| 2027 |
$10.4m
918.53%
unlock
|
|
3 Pluristem Therapeutics Inc. Analysts have issued a net profit forecast 2027. The average Pluristem Therapeutics Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Net Profit Estimates
| 2026 | $-23.8m | 5.49% |
|---|---|---|
| 2027 |
$-21.0m
11.96%
unlock
|
|
Net Margin
| 2026 | -2,335.29% | 38.59% |
|---|---|---|
| 2027 |
-201.84%
91.36%
unlock
|
|
Earnings per share, P/E ratio and EV/sales Estimates 2027, 2028 & 2029
| Jun '26 |
2027 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -2.44 | -1.94 |
| 31.46% | 20.49% | |
| P/E | negative | |
| EV/Sales | 3.21 |
3 Analysts have issued a Pluristem Therapeutics Inc. forecast for earnings per share. The average Pluristem Therapeutics Inc. EPS is
This results in the following potential growth metrics and future valuations:
Earnings Per Share
| 2026 | $-2.44 | 31.46% |
|---|---|---|
| 2027 |
$-1.94
20.49%
unlock
|
|
P/E ratio
| Current | -0.47 | 67.75% |
|---|---|---|
| 2027 |
-0.54
14.67%
unlock
|
|
Based on analysts' sales estimates for 2027, the Pluristem Therapeutics Inc. stock is valued at an EV/Sales of
This results in the following potential growth metrics and future valuations:
EV/Sales
| Current | 32.73 | 6.83% |
|---|---|---|
| 2027 |
3.21
90.18%
unlock
|
|
P/S ratio
| Current | 12.71 | 65.11% |
|---|---|---|
| 2027 |
1.25
90.18%
unlock
|
|
Pluristem Therapeutics Inc....
Current Pluristem Therapeutics Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Alliance Global Partners |
Locked
➜
Locked
|
Locked | Jun 02 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Alliance Global Partners:
Locked
➜
Locked
|
Jun 02 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
